TQB-2868

N/A

Report date: 2026/05/09 20:00:18

Base Information

Drug NameTQB-2868
Drug Alias NameTQB-2868
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionProgrammed cell death protein 1 blockersTransforming growth factor beta inhibitors
TargetsProgrammed cell death protein 1Transforming growth factor beta
Therapy Area/IndicationsUterine Cervical NeoplasmsPancreatic NeoplasmsBile Duct Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co LtdFudan UniversityNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
Inactive CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Active IndicationsPancreatic NeoplasmsBile Duct NeoplasmsCarcinoma, Hepatocellular +[4] 
Inactive IndicationsUterine Cervical NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A